Qamar Khan
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Qamar Khan sits in the upper half of US sponsors by registered trial count (#4,887 of 15,751 sponsors by registered trial count).
Qamar Khan: 2 sponsored US clinical trials, none currently recruiting.
Qamar Khan sponsors 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 1 trials.
Mid-pack sponsor footprint
Qamar Khan is in the upper half of sponsors by trial count (#4,887 of 15,751 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Indexed trials (enrollment closed)
2 total, page 1 of 1
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Therapeutic Areas
How the Qamar Khan early-phase archive is shaped
2 indexed studies, none listed as recruiting (0% open); 1 completed (50%).
Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.